Dermatomyositis
Clinical Snapshot
Dermatomyositis (DM) is an autoimmune inflammatory myopathy that combines proximal, symmetric skeletal muscle weakness with a set of highly characteristic — in several cases genuinely pathognomonic — skin findings. It belongs to the broader family of idiopathic inflammatory myopathies (IIM), which also includes polymyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, inclusion body myositis, and the overlap myositides.[1] DM is set apart from these other IIM subtypes by its underlying mechanism: a humoral, complement-mediated microangiopathy in which autoantibodies and activated complement — culminating in the C5b-9 membrane attack complex — deposit in the small blood vessels of both skin and endomysium, causing capillary loss, tissue ischemia, and the perifascicular pattern of muscle-fiber atrophy that is the biopsy hallmark of the disease.[1] This is a fundamentally different mechanism from polymyositis, in which cytotoxic CD8+ T cells directly invade and destroy individual myofibers with no comparable capillary-mediated process and, critically, no skin involvement at all — the presence or absence of the cutaneous findings below is the single most useful bedside feature separating the two conditions.[1]
DM affects both children (as juvenile dermatomyositis, JDM) and adults, with a roughly 2- to 3-fold female predominance in most adult series.[1] A genuinely Canadian cohort of 114 adults followed at 2 Ontario tertiary care centres over 13 years found a mean age at diagnosis of 59 years and a female predominance of 80%, with skin and muscle involvement presenting together in 63% of patients and skin preceding muscle disease in a further 11%.[2] The same cohort found interstitial lung disease (ILD) in 39% of patients and creatine kinase elevation in only 66% of confirmed cases — a normal CK does not exclude the diagnosis.[2]
Two features of DM carry outsized clinical importance and run through this entire chapter. First, adult-onset DM has a well-established paraneoplastic association: a clinically meaningful proportion of adults — particularly those diagnosed at age 40 or older — have or will develop an underlying malignancy within a few years of DM onset, and age-appropriate cancer screening plus a formal risk-stratified assessment for enhanced screening is a mandatory, non-negotiable part of the initial work-up, not an optional add-on.[3] Second, DM can present with its characteristic skin findings and little or no detectable muscle disease — clinically amyopathic dermatomyositis (CADM) — a presentation that is anything but reassuring, since it is strongly linked to a specific autoantibody (anti-MDA5) and a rapidly progressive, often fatal interstitial lung disease.
Recognize the Condition
Cutaneous findings
The cutaneous findings of DM are frequently the presenting feature and, in several cases, are pathognomonic enough on their own to prompt the diagnosis before any weakness is apparent.[1]
- Heliotrope rash — violaceous to erythematous discoloration confined to the upper eyelids, often with periorbital edema; the name comes from its resemblance to the purple heliotrope flower. Found in 66% of the Canadian Ontario cohort.[2]
- Gottron's papules — the most pathognomonic finding in DM: flat-topped, erythematous-to-violaceous papules and plaques over bony prominences, most classically the metacarpophalangeal and interphalangeal joints, but also the elbows, knees, and medial malleoli. Present in 69% of the Canadian cohort — its single most common cutaneous finding.[2] Gottron's sign refers to the same distribution without discrete papules — flat macular erythema instead.
- Shawl sign and V-sign — symmetric, photodistributed erythema across the posterior neck, upper back, and shoulders (shawl sign) or the anterior neck and upper chest in a V-shaped distribution (V-sign); found in 56% and 61% of the Canadian cohort respectively.[2]
- Mechanic's hands — hyperkeratotic, fissured, rough, "dirty"-appearing skin along the radial and palmar aspects of the fingers, resembling the hands of a manual labourer; classically associated with antisynthetase syndrome (below) but seen in DM more broadly.
- Holster sign — poikilodermatous erythema over the lateral hip and thigh.
- Periungual changes — periungual telangiectasia, ragged cuticles, and cuticular overgrowth are common and easy to miss without deliberately examining the nail folds.
- Poikiloderma — a combination of hyper- and hypopigmentation, telangiectasia, and skin atrophy in photodistributed areas.
- Calcinosis cutis — subcutaneous or intracutaneous calcium deposits; uncommon in adult-onset DM but a genuinely important complication in juvenile DM (see Special Populations and Complications, within Monitoring and Follow-Up).
The rash is frequently intensely pruritic — more so than the rash of cutaneous lupus erythematosus, which it can otherwise closely resemble — and photosensitive, with sun exposure a genuine trigger for flares.[1]
Muscle findings
Classic DM produces symmetric, proximal muscle weakness developing over weeks to months — difficulty rising from a low chair, climbing stairs, or lifting the arms overhead (to comb hair or reach a shelf) are the typical presenting complaints. Neck flexors are often disproportionately weak relative to neck extensors. Muscle involvement is usually painless or only mildly tender, which can mislead a clinician expecting muscle disease to hurt; myalgia and mild tenderness do occur but are not the dominant feature. Fatigue, low-grade fever, and modest weight loss are common associated constitutional symptoms.[1]
Clinically amyopathic dermatomyositis (CADM) — a distinct, high-stakes presentation
A meaningful subset of patients — historically estimated at around 20% of all DM — have the characteristic skin findings above with no objective muscle weakness, and normal or only minimally abnormal creatine kinase, EMG, and muscle biopsy findings sustained for 6 months or longer from rash onset. This is clinically amyopathic dermatomyositis (CADM), sometimes further split into true amyopathic DM (no biopsy, EMG, or enzyme abnormality at all) and hypomyopathic DM (subclinical laboratory or biopsy abnormality without clinically apparent weakness).
CADM is not a reassuring, milder variant of DM. It is strongly associated with the anti-MDA5 autoantibody, and anti-MDA5-positive CADM carries a disproportionate risk of rapidly progressive interstitial lung disease (RP-ILD) — a fulminant, often treatment-refractory pneumonitis that can progress to respiratory failure and death within days to weeks, frequently before muscle weakness ever develops. Do not let a normal strength examination lower your suspicion for serious internal-organ disease in a patient with classic DM skin findings — pursue anti-MDA5 testing and pulmonary work-up urgently regardless of muscle strength (see Red Flags and Investigations, within Assessment and Diagnosis).
Antisynthetase syndrome overlap features
A separate but overlapping presentation is defined by antibodies against aminoacyl-tRNA synthetases, anti-Jo-1 being the most common. Antisynthetase syndrome combines myositis — which may have DM-type skin findings or occur without them — with some combination of ILD, inflammatory polyarthritis, mechanic's hands, Raynaud phenomenon, and fever. Its associated ILD typically follows a more indolent, chronic course than anti-MDA5-associated RP-ILD, though it still carries meaningful morbidity and needs the same proactive pulmonary surveillance described below.
Risk Factors
- Female sex — adult-onset DM shows an approximately 2- to 3-fold female predominance in most series, though paraneoplastic DM specifically skews toward older age and male sex.[1]
- Age — DM has a bimodal age distribution: a childhood peak (juvenile DM, most commonly presenting between about 5 and 15 years) and an adult peak in the 40s to 60s; the Canadian Ontario cohort's mean age at diagnosis was 59 years.[2]
- Genetic susceptibility — certain HLA class II alleles are overrepresented in DM, though genetic risk alone is insufficient to cause disease and no single gene test is used clinically.
- Ultraviolet light exposure — a recognized environmental trigger and exacerbant of cutaneous disease activity; geographic and seasonal patterns of DM-specific autoantibodies (particularly anti-TIF1-gamma and anti-Mi2) correlate with regional UV intensity.[1]
- Certain medications and exposures — statins are more classically linked to a related but distinct entity, immune-mediated necrotizing myopathy (anti-HMGCR antibody), but drug-induced dermatomyositis-like eruptions (for example with hydroxyurea) and immune-checkpoint-inhibitor-associated inflammatory myopathy (which can include DM-pattern disease) are both recognized.
Malignancy association — a critical safety point
Adult-onset DM carries a well-established paraneoplastic association: cancer is diagnosed within roughly 3 years before or after DM onset in a clinically meaningful proportion of adult patients, with risk significantly elevated relative to the general population in this window.[3] The most commonly reported associated malignancies vary by population studied but consistently include breast, lung, ovarian, gastric, colorectal, and pancreatic cancers, non-Hodgkin lymphoma, and — particularly in some Asian cohorts — nasopharyngeal cancer.[3]
Specific clinical and serologic features meaningfully raise the probability of an associated malignancy and drive the risk-stratified screening approach detailed in Investigations (within Assessment and Diagnosis):[3]
- Age 40 years or older at DM diagnosis — the single most consistently reported clinical risk factor.
- Anti-TIF1-gamma or anti-NXP2 myositis-specific antibody positivity in an adult — both are strong markers of cancer-associated DM (see the antibody table in Assessment and Diagnosis); critically, this same antibody association does not hold in children (see Special Populations).
- Male sex, rapid disease onset, cutaneous ulceration or vasculitis, dysphagia, and disease that is persistently active or resistant to first-line immunosuppression.[3]
Treat this as a genuine safety issue rather than a background statistic: every newly diagnosed adult with DM needs both age-appropriate cancer screening and a formal risk-stratified assessment for enhanced screening, pursued in parallel with starting immunosuppressive treatment — not deferred until treatment response is assessed (see Investigations and Red Flags).
Red Flags & Refer
Any of the following changes the urgency of the assessment, and often the treatment plan itself:
- New dyspnea, dry cough, hypoxia, or a falling oxygen saturation — especially in a patient with anti-MDA5 or antisynthetase antibody positivity, or with clinically amyopathic disease. Treat as possible rapidly progressive interstitial lung disease (RP-ILD) until proven otherwise: this can progress to respiratory failure within days and needs urgent high-resolution CT, pulmonary function testing, and specialist involvement, often with aggressive combination immunosuppression started immediately rather than escalated sequentially (see Choose Initial Treatment).
- Rapidly progressive proximal weakness, or any suggestion of respiratory muscle or diaphragmatic weakness (orthopnea, a weak cough, breathlessness out of proportion to any lung findings) — assess for impending ventilatory failure; this is a medical emergency distinct from, but sometimes coexisting with, RP-ILD.
- New or worsening dysphagia — pharyngeal muscle weakness in DM carries a genuine aspiration risk, including silent aspiration with no obvious choking or coughing; dysphagia affects roughly one in three patients with DM.[4] Arrange a formal swallowing assessment and consider diet modification or NPO status until it is complete, rather than assuming a sore throat or reflux explanation (see Non-Pharmacologic Treatment).
- Cutaneous ulceration or digital infarction — a marker of underlying vasculopathy and one of the clinical features that independently raises the probability of an associated malignancy; needs prompt dermatology or rheumatology evaluation.
- Any systemic symptom in a patient 40 years or older at DM diagnosis — unexplained weight loss, gastrointestinal bleeding or altered bowel habit, new pelvic or breast symptoms, hematuria, or similar — needs prompt, targeted investigation for an underlying malignancy outside the routine risk-stratified screening interval, not reassurance that "screening is already booked."
- Disease that is not responding as expected to appropriate immunosuppression — treatment-refractory DM is itself a recognized red flag for an undetected malignancy and should prompt re-review of the cancer-screening status, not simply an automatic escalation to the next immunosuppressive agent.
- New chest pain, palpitations, or unexplained heart failure symptoms — myocarditis and conduction abnormalities are uncommon but recognized DM complications; investigate rather than attributing every symptom to deconditioning or corticosteroid effect.
- In juvenile DM, new acute abdominal pain — gastrointestinal vasculopathy can progress to bowel ulceration or perforation, a pediatric emergency (see Special Populations).
Assessment & Diagnosis
Diagnostic approach
No single test confirms DM in isolation. Diagnosis rests on a combination of the characteristic clinical picture (the muscle-weakness pattern plus the cutaneous findings in Recognize the Condition), muscle-enzyme and autoantibody testing, electromyography, imaging, and — where the diagnosis is not clinically clear-cut — muscle and/or skin biopsy.[1] The 2017 EULAR/ACR classification criteria formalize this combination into a validated probability score (below).[5]
Laboratory testing
Creatine kinase (CK) is the most commonly used muscle enzyme and is elevated in most, but not all, patients with active myositis — the Canadian Ontario cohort found CK elevated in only 66% of confirmed DM cases, underscoring that a normal CK does not exclude the diagnosis, particularly in clinically amyopathic disease.[2] Aldolase is a useful adjunct precisely because it is enriched in fascia as well as muscle and can be elevated even when CK is normal. AST, ALT, and LDH are also frequently elevated as nonspecific markers of muscle breakdown, and are easy to misattribute to primary liver disease if the clinician is not thinking about myositis. ANA is positive in the majority of patients but is nonspecific. CRP and ESR are often only mildly elevated and correlate poorly with disease activity — do not rely on a normal inflammatory-marker panel to exclude active DM.
Myositis-specific and myositis-associated antibodies
Testing for myositis-specific antibodies (MSAs) and myositis-associated antibodies (MAAs) is central to modern DM care: these antibodies define clinically distinct subgroups with different organ-involvement patterns, malignancy risk, and prognosis, and directly inform both the intensity of interstitial lung disease surveillance and the intensity of cancer screening.[1]
| Antibody | Clinical association |
|---|---|
| Anti-Mi2 | Classic DM with prominent skin disease (Gottron's papules, heliotrope rash, shawl/V-sign); relatively good treatment response and lower rates of ILD or malignancy than other DM-specific antibodies. |
| Anti-TIF1-gamma (anti-p155/140) | The strongest antibody marker of malignancy-associated DM in adults. In juvenile DM the same antibody does not carry this malignancy signal, and is instead linked to more severe cutaneous disease (see Special Populations). |
| Anti-NXP2 (anti-MJ) | Also linked to malignancy risk in adults; in children, associated with calcinosis and more severe disease rather than malignancy. |
| Anti-MDA5 | Strongly associated with clinically amyopathic/hypomyopathic DM and rapidly progressive interstitial lung disease (RP-ILD) — the single highest-mortality DM antibody subgroup; also linked to cutaneous ulceration, tender palmar papules ("MDA5 hands"), and arthritis. |
| Anti-SAE | Often presents with cutaneous disease first, myositis and dysphagia developing later; some malignancy association reported. |
| Anti-Jo-1 and other anti-aminoacyl-tRNA synthetase antibodies (anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, and others) | Define antisynthetase syndrome: myositis plus some combination of ILD (typically a more indolent, chronic course than anti-MDA5-associated RP-ILD), inflammatory arthritis, mechanic's hands, Raynaud phenomenon, and fever; carries a real ILD burden but generally better long-term survival than anti-MDA5-associated disease. |
| Anti-Ro52 (often co-positive with another myositis-specific antibody) | Not DM-specific on its own, but co-positivity alongside an anti-synthetase or anti-MDA5 antibody is linked to more severe ILD. |
Electromyography, imaging, and biopsy
Electromyography (EMG) in active myositis classically shows increased insertional and spontaneous activity (fibrillation potentials, positive sharp waves) together with short-duration, low-amplitude, polyphasic motor unit potentials — a myopathic rather than neurogenic pattern. EMG is abnormal in roughly 70-90% of DM cases and is most useful for confirming a myopathic process and excluding a primary neurogenic cause of weakness.
MRI, using fat-suppressed T2-weighted or short-tau inversion recovery (STIR) sequences, shows muscle edema corresponding to active inflammation, and can distinguish this from the fatty replacement of chronic, burnt-out muscle damage or from corticosteroid-induced myopathy — a genuinely useful distinction when a patient on treatment is not improving and it is unclear whether under-treated disease or a steroid-related complication is to blame. MRI findings can also help select the optimal muscle biopsy site.
Muscle biopsy remains the most direct confirmatory test and is particularly valuable when the diagnosis is not clinically clear-cut. The hallmark finding is perifascicular atrophy — atrophic muscle fibers concentrated at the periphery of the fascicle, reflecting the capillary-mediated ischemia described in Overview — together with a perimysial and perivascular (rather than purely endomysial) inflammatory infiltrate and, on immunohistochemistry, evidence of complement membrane-attack-complex deposition on small vessels. Perifascicular atrophy is not universally present and can also occur in antisynthetase-syndrome-associated myositis, so biopsy findings are interpreted alongside the full clinical and serologic picture rather than in isolation.[1] Skin biopsy can support the diagnosis when muscle disease is absent or minimal (clinically amyopathic disease), though the histologic findings (an interface dermatitis) substantially overlap with cutaneous lupus erythematosus and are not reliably distinguishing on their own.
2017 EULAR/ACR classification criteria
The 2017 EULAR/ACR classification criteria are the most widely used, data-driven framework for classifying suspected IIM and its major subgroups, developed and validated against 976 IIM patients and 624 patients with mimicking conditions.[5] The criteria combine weighted items across several domains into a single probability score, calculated with or without muscle-biopsy data:
| Domain | What is scored |
|---|---|
| Onset and pattern | Age at first symptom onset, and objective symmetric proximal muscle weakness with neck flexors relatively weaker than neck extensors |
| Skin findings | Heliotrope rash, Gottron's papules, and Gottron's sign — the presence of any of these adds substantially to the score and is central to distinguishing DM from polymyositis |
| Other clinical features | Dysphagia or esophageal dysmotility |
| Laboratory | Elevated CK, LDH, AST, or ALT; anti-Jo-1 (or another anti-synthetase) antibody positivity |
| Electromyography | A myopathic, rather than neurogenic or normal, pattern |
| Muscle biopsy (if performed) | Endomysial inflammatory infiltrate surrounding, but not invading, myofibers; perimysial and/or perivascular inflammatory infiltrate; perifascicular atrophy; rimmed vacuoles |
A weighted score of 5.5 (55% probability) without biopsy data, or 6.7 with biopsy data, classifies a patient as having probable IIM; a score of 7.5 (90% probability) without biopsy, or 8.7 with biopsy, classifies definite IIM — sensitivity and specificity both improve when muscle-biopsy findings are included in the calculation.[5] Once a patient meets the overall probability threshold, a separate classification tree subclassifies the case into DM, polymyositis, inclusion body myositis, or (in children) juvenile DM, weighted heavily by the presence or absence of the characteristic skin findings above.[5] Use this framework as a structured classification aid alongside clinical judgement, not as a substitute for it — a patient with a textbook heliotrope rash and Gottron's papules who does not yet meet the full probability threshold should still be treated clinically as having DM.
Differential diagnosis
- Polymyositis — proximal weakness without the DM-specific skin findings; endomysial (rather than perifascicular/perivascular) inflammatory infiltrate on biopsy, with T cells directly surrounding and invading non-necrotic fibers.
- Antisynthetase syndrome — see Recognize the Condition; can overlap substantially with DM.
- Immune-mediated necrotizing myopathy — often statin-associated (anti-HMGCR antibody) or paraneoplastic/idiopathic (anti-SRP antibody); biopsy shows myofiber necrosis with minimal inflammatory infiltrate and no perifascicular atrophy.
- Inclusion body myositis — typically older patients, insidious asymmetric weakness affecting both proximal and distal muscles (classically finger flexors and quadriceps), and a poor response to immunosuppression; biopsy shows rimmed vacuoles.
- Overlap myositis — myositis occurring alongside another connective tissue disease (systemic lupus erythematosus, systemic sclerosis, mixed connective tissue disease, Sjögren disease).
- Drug-induced or toxic myopathy — statins, corticosteroids themselves (a non-inflammatory steroid myopathy that can be mistaken for undertreated DM), colchicine, and others.
- Endocrine myopathy — hypothyroidism and Cushing syndrome (see that chapter) can both produce proximal weakness without the inflammatory or cutaneous features of DM.
- Cutaneous lupus erythematosus — for skin-predominant presentations; malar or discoid lesions typically spare the nasolabial folds and lack the periungual and Gottron-distribution findings of DM.
- Psoriasis and seborrheic dermatitis — psoriatic plaques over the knuckles can superficially resemble Gottron's papules; periorbital seborrheic dermatitis can be mistaken for a mild heliotrope rash.
Mandatory malignancy screening
Every newly diagnosed adult needs age-appropriate cancer screening per standard population guidelines (mammography, cervical screening, colorectal screening, and so on) as a non-negotiable baseline. Layered on top of this, the 2023 International Myositis Assessment and Clinical Studies Group (IMACS) guideline provides an evidence-based, risk-stratified framework for additional, DM-specific cancer screening.[3] Patients are stratified into standard, moderate, or high cancer-risk categories based on IIM subtype, myositis-specific antibody status (anti-TIF1-gamma and anti-NXP2 confer high risk in adults), age 40 years or older at onset, and the clinical features in Risk Factors. Screening intensity is matched to risk category using a basic panel (history and examination, routine bloodwork, and chest radiography) for standard-risk patients, escalating to an enhanced panel — contrast CT of the chest, abdomen, and pelvis, tumour markers, and consideration of mammography or breast imaging, gynecologic ultrasound, and, in appropriate populations, nasoendoscopy or PET-CT — for moderate- and high-risk patients.[3] For high-risk patients, the guideline recommends repeating this structured screening at 1, 2, and 3 years after diagnosis, reflecting the well-documented multi-year risk window around DM onset.[3]
Baseline interstitial lung disease screening
Because ILD is common (39% in the Canadian Ontario cohort) and can be clinically silent until it is advanced or rapidly progressive, obtain baseline high-resolution CT (HRCT) of the chest and pulmonary function testing (including diffusing capacity, DLCO) in every newly diagnosed patient, not only those with respiratory symptoms.[2] Repeat and intensify surveillance based on antibody status — anti-MDA5- and antisynthetase-antibody-positive patients need closer, more proactive follow-up — and with any new respiratory symptom (see Red Flags and Monitoring and Follow-Up).
Treatment Targets
- Suppress inflammation and induce remission of both the muscle and skin components of disease — treating the myositis alone and assuming the skin will simply follow is a common and avoidable error (see Common Errors to Avoid).
- Prevent and limit muscle damage, weakness, and long-term functional disability by starting effective treatment promptly.
- Screen for, and where found, coordinate treatment of an underlying malignancy in parallel with immunosuppressive therapy — a genuine treatment goal in its own right, not a one-time box to check at diagnosis.
- Detect and manage interstitial lung disease early, before it can progress to rapidly progressive, treatment-refractory respiratory failure.
- Protect against aspiration and malnutrition in patients with dysphagia.
- Minimize corticosteroid-related morbidity through an early steroid-sparing strategy rather than prolonged high-dose monotherapy.
- Support function, quality of life, and psychosocial wellbeing through a chronic, relapsing-remitting disease course with a disfiguring and often intensely pruritic rash.
Choose Initial Treatment
Induction — high-dose corticosteroids plus an early steroid-sparing agent
1st line oral prednisone 0.5-1 mg/kg/day PO, usually 40-60 mg/day and up to 1 mg/kg/day for more severe disease.[6] For rapidly progressive weakness, respiratory muscle involvement, severe dysphagia, or suspected rapidly progressive interstitial lung disease, IV methylprednisolone pulse therapy (commonly 500-1000 mg/day for 3 days) is used to gain more rapid disease control before transitioning to an oral maintenance dose.[6]
Start concomitantly, not sequentially the modern standard of care is to add a steroid-sparing agent from the outset, alongside the induction corticosteroid course, rather than waiting to see whether the patient fails steroid monotherapy or develops steroid-related complications first — this shortens the time to a safe corticosteroid taper and reduces cumulative steroid exposure.[6] Methotrexate 15-25 mg PO or SC once weekly (with folic acid supplementation per usual practice) or azathioprine 2-3 mg/kg/day PO are the standard first-choice steroid-sparing agents; mycophenolate mofetil 2-3 g/day PO in divided doses and tacrolimus (dosed to a target trough level) are reasonable alternatives, particularly when interstitial lung disease is a prominent feature.[6]
Cutaneous-predominant or refractory skin disease
DM's cutaneous manifestations are frequently more resistant to corticosteroids than the myositis itself, and are easy to under-treat if a clinician focuses on strength and CK alone. Adjunct for skin disease hydroxychloroquine 200-400 mg/day PO (dosed to actual body weight per current ophthalmologic guidance, not to exceed about 5 mg/kg/day) alongside strict photoprotection (see Non-Pharmacologic Treatment); a topical corticosteroid such as clobetasol propionate can be used for localized, particularly stubborn areas.
Refractory or severe disease
Refractory muscle disease, severe dysphagia, or when infection risk limits further immunosuppression intravenous immunoglobulin (IVIG) 2 g/kg IV, divided over 2-5 days and repeated approximately every 4 weeks, is the best-evidenced agent specifically for DM: in the randomized ProDERM trial, 79% of IVIG-treated patients met the primary response criterion at 16 weeks versus 44% on placebo.[7] Watch for infusion-related and thromboembolic adverse effects, which occurred at a meaningfully higher rate in the treatment arm of that trial (see Monitoring and Follow-Up).[7]
Refractory to the above, myositis-antibody-positive disease, or juvenile-onset disease rituximab, per specialist-directed protocol (commonly 375 mg/m² IV weekly for 4 doses, or 1 g IV x2 doses 2 weeks apart). In the randomized RIM trial of refractory adult and juvenile DM/PM, 83% of patients eventually met the trial's definition of improvement, though its placebo-phase design — every patient eventually received rituximab — makes the timing of response, rather than the overall response rate, the trial's key finding; response was not meaningfully different between earlier and later rituximab initiation.[8] Rituximab appears particularly effective in myositis-autoantibody-positive patients and in juvenile-onset disease.[6]
Anti-MDA5-associated rapidly progressive interstitial lung disease — treat as an emergency
Do not step therapy up sequentially here anti-MDA5-associated RP-ILD carries a genuinely high mortality risk and is generally managed with aggressive combination immunosuppression from the outset — high-dose corticosteroids plus a calcineurin inhibitor (tacrolimus or ciclosporin) plus IVIG and/or rituximab, with cyclophosphamide reserved for the most severe or progressive cases — coordinated urgently with a tertiary rheumatology/ILD centre rather than escalated one agent at a time as in more typical DM.
Non-Pharmacologic Treatment
Photoprotection
Ultraviolet exposure is a genuine trigger for cutaneous disease activity. Advise broad-spectrum, high-SPF sunscreen used consistently (not only on sunny days), sun-protective clothing, and avoidance of peak-UV hours — simple, low-risk measures that meaningfully reduce flares of the rash.
Exercise and rehabilitation
Once inflammation is reasonably controlled, a graded, supervised exercise and physical/occupational therapy program improves strength and function without provoking a disease flare — this reflects a genuine shift from older teaching that recommended rest; current evidence supports early, carefully supervised mobilization. Energy conservation strategies help with the disabling fatigue many patients report even outside of active flares.
Skin care and pruritus management
The DM rash is frequently more pruritic than that of cutaneous lupus erythematosus. Gentle, fragrance-free skin care, avoidance of known irritants, and standard antipruritic measures (oral antihistamines, topical agents) provide meaningful symptomatic relief alongside definitive immunosuppressive treatment of the underlying disease.
Swallowing and nutrition
Arrange a formal speech-language pathology swallowing assessment for any patient with dysphagia (see Red Flags), with diet-texture modification, safe-swallowing positioning strategies, and close nutritional monitoring; escalate to enteral feeding support if oral intake cannot safely meet nutritional needs.
Bone health and infection prevention around corticosteroid use
Weight-bearing exercise where feasible, adequate calcium and vitamin D intake, and confirmation of age-appropriate vaccination status (with avoidance of live vaccines during significant immunosuppression) before or early in a corticosteroid/immunosuppressant course are standard supportive measures (see Monitoring and Follow-Up for the full corticosteroid-monitoring bundle).
Smoking cessation
Advise smoking cessation in every patient, but particularly those with interstitial lung disease, where ongoing smoking compounds respiratory risk.
Patient and caregiver education
- Set expectations early: DM is typically a chronic, relapsing-remitting disease, and steroid-sparing agents (methotrexate, azathioprine, mycophenolate) take weeks to months to reach full effect — explain this delay explicitly so a patient does not lose confidence in a new medication that has not yet had time to work.
- Explain clearly why extensive cancer screening is being arranged even though the patient may feel well and has no cancer symptoms — this is a routine, evidence-based part of DM care, not a sign that something specific has already been found.
- Review the specific symptoms that should prompt urgent contact rather than waiting for the next scheduled visit (see Red Flags) — new shortness of breath or cough, worsening swallowing, and rapidly progressive weakness chief among them.
- For families of children with juvenile DM, explain the calcinosis risk and the rationale for aggressive early treatment specifically to reduce that risk (see Special Populations).
Special Populations
Juvenile dermatomyositis (JDM)
JDM is a genuinely distinct presentation, not simply DM in a smaller body. Different from adults routine malignancy screening is not warranted in juvenile-onset IIM — a strong recommendation reflecting the much lower paraneoplastic association in children.[6] Critically, the same anti-TIF1-gamma antibody that signals high malignancy risk in an adult does not carry that signal in a child; in JDM it is instead associated with more severe cutaneous disease, and anti-NXP2 is linked to a higher risk of calcinosis rather than malignancy.[1] First-line therapy a combination of high-dose glucocorticoid and methotrexate from the outset, rather than glucocorticoid monotherapy, per the SHARE consensus-based recommendations.[9] Aggressive early treatment measurably reduces the incidence of calcinosis, a complication that is far more common and clinically significant in JDM than in adult-onset disease.[9] Routine pulmonary function testing, including diffusing capacity, is recommended in children given that ILD can be present and clinically silent.[6]
Pregnancy
Active DM can worsen, or first present, during pregnancy, and active disease is linked to a higher risk of miscarriage, preterm birth, and intrauterine growth restriction — achieving disease control before conception is preferred whenever the clinical situation allows planning. Prednisone, azathioprine, hydroxychloroquine, and IVIG are generally considered compatible with pregnancy. Avoid methotrexate and mycophenolate mofetil, both established teratogens — discontinue with an adequate washout period before conception whenever pregnancy is planned, and manage collaboratively with maternal-fetal medicine.
Older adults and age 40 years or older at diagnosis
This is the population at highest risk of an associated malignancy (see Risk Factors and Investigations, within Assessment and Diagnosis) and needs the most vigilant risk-stratified cancer screening. As in many rheumatologic conditions treated with long-term corticosteroids, it is also a population where bone, glucose, infection, and gastrointestinal monitoring (see Monitoring and Follow-Up) deserves particular attention given age-related baseline risk.
Anti-MDA5-positive and clinically amyopathic disease
Patients in this subgroup need proactive, urgent interstitial lung disease work-up (HRCT and pulmonary function testing) at diagnosis regardless of muscle strength or symptoms, and a low threshold to treat aggressively and early if any respiratory symptom develops (see Red Flags and Choose Initial Treatment).
Renal impairment
Avoid methotrexate when eGFR is under 50 mL/min/1.73 m², per current Canadian product labelling. IVIG carries its own renal considerations and needs adequate hydration and careful dosing in reduced renal function.
Hepatic impairment
Azathioprine and methotrexate both carry hepatotoxicity risk and need closer monitoring, or an alternative agent, in significant hepatic impairment; mycophenolate mofetil's comparatively lower hepatotoxicity profile can make it the preferred alternative in this situation.
Monitoring & Follow-Up
Disease-activity monitoring
Track functional strength (manual muscle testing or a validated functional index) at every visit rather than relying on CK/aldolase trends alone — enzyme levels can dissociate from clinical strength, particularly later in the disease course, and chasing a lab value rather than the patient's actual function is a recognized pitfall.
Interstitial lung disease surveillance
Repeat pulmonary function testing (including DLCO) and/or HRCT at intervals matched to baseline risk — more frequently and proactively in anti-MDA5- or antisynthetase-antibody-positive patients — and immediately with any new respiratory symptom (see Red Flags). Serum ferritin can be a useful adjunct biomarker of disease activity specifically in anti-MDA5-associated disease, correlating with treatment response in some reports.
Cancer-screening follow-up
For patients risk-stratified as high risk, continue structured screening (basic plus enhanced panels as indicated) at 1, 2, and 3 years after diagnosis, reflecting the multi-year window of elevated malignancy risk around DM onset.[3] Reassess risk stratification, and screening status, at any point disease becomes unexpectedly treatment-refractory (see Red Flags).
Corticosteroid monitoring
- Vitamin D supplementation, adequate calcium intake, and bisphosphonate therapy for fracture prevention where indicated, alongside usual bone-density monitoring.
- Regular blood pressure and blood glucose monitoring.
- A proton pump inhibitor for corticosteroid-related gastroesophageal reflux where clinically indicated.
Steroid-sparing agent monitoring
- Methotrexate: routine CBC, liver enzymes, and renal function per usual practice; confirm eGFR before dose adjustments.
- Azathioprine: dose according to TPMT activity where available; monitor CBC and liver enzymes regularly.
- Mycophenolate mofetil: monitor CBC and for signs of infection.
- Hydroxychloroquine: baseline and annual ophthalmologic screening for retinopathy after 5 years of use, sooner with renal impairment, tamoxifen use, or pre-existing retinal disease.
- IVIG: monitor renal function and for signs of thromboembolism — both were notable adverse-event signals in the ProDERM trial.[7]
- Rituximab: monitor B-cell counts, immunoglobulin levels, and for infection per specialist-directed protocol.
Dysphagia and calcinosis follow-up
Reassess swallowing function periodically in any patient with a history of dysphagia, even after apparent improvement.[4] In juvenile DM, monitor for new or progressive calcinosis at routine visits (see Special Populations).
Common Errors to Avoid
- Treating a normal creatine kinase as ruling out dermatomyositis — amyopathic and hypomyopathic disease can have normal CK, aldolase, EMG, and biopsy findings despite unmistakable skin disease.
- Reassuring a patient with classic DM skin findings and normal strength that "at least the muscles aren't involved," rather than urgently pursuing anti-MDA5 testing and pulmonary work-up — clinically amyopathic disease carries a disproportionate rapidly progressive interstitial lung disease risk.
- Waiting for corticosteroid monotherapy to fail before starting a steroid-sparing agent, rather than starting one concomitantly from the outset.
- Treating the skin disease as an afterthought once the myositis responds to corticosteroids — DM's cutaneous findings are frequently more corticosteroid-resistant than the muscle disease and often need their own additional therapy (hydroxychloroquine, photoprotection).
- Deferring or skipping risk-stratified cancer screening because the patient feels well, has already started treatment, or "screening can wait until follow-up" — screening should proceed in parallel with immunosuppression, not be sequenced after it.
- Applying the same aggressive, adult-style malignancy-screening approach to a child with juvenile DM — routine cancer screening is not warranted in juvenile-onset disease, and over-testing carries its own costs and anxiety.
- Assuming an anti-TIF1-gamma-positive result carries the same high malignancy signal in a child that it does in an adult — the antibody's prognostic meaning genuinely differs by age.
- Attributing new dysphagia in a DM patient to gastroesophageal reflux and simply prescribing a proton pump inhibitor without assessing pharyngeal muscle strength and aspiration risk.
- Screening for interstitial lung disease only once a patient becomes symptomatic, rather than obtaining baseline HRCT and pulmonary function testing in every newly diagnosed patient.
- Continuing methotrexate without checking renal function, or continuing it despite eGFR falling under 50 mL/min/1.73 m².
- Chasing a normalizing CK as the sole marker of adequate treatment response while a patient's actual functional strength has not meaningfully improved.
- Escalating immunosuppression step-by-step in anti-MDA5-associated rapidly progressive interstitial lung disease as though it were routine DM, rather than recognizing it as an emergency warranting aggressive combination therapy from the outset.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Induction Corticosteroid Therapy
First-line for every newly diagnosed patient; start a steroid-sparing agent concomitantly rather than waiting for steroid failure or a full taper.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Prednisone | Initial: 0.5-1 mg/kg/day PO (usually 40-60 mg/day) | Hyperglycemia, hypertension, osteoporosis, GI upset, mood changes, infection risk, adrenal suppression with prolonged use | Additive hyperglycemia with other diabetogenic drugs; reduced vaccine response during immunosuppressive dosing | Begin tapering once disease control is achieved and the steroid-sparing agent has had time to take effect. |
| Methylprednisolone (IV pulse) | Pulse dose: 500-1000 mg IV once daily for 3 days, then transition to oral maintenance | Hyperglycemia, mood changes, rarely arrhythmia with rapid infusion | Additive hyperglycemia with other diabetogenic drugs | Reserved for rapidly progressive weakness, respiratory muscle involvement, severe dysphagia, or suspected rapidly progressive interstitial lung disease. |
Steroid-Sparing Agents (Start Concomitantly With Induction)
Onset of effect is delayed by weeks to months — start alongside the induction corticosteroid course, not after it fails.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Methotrexate | Adults: 15-25 mg PO or SC once weekly | Hepatotoxicity, myelosuppression, GI upset, mucositis, rare pulmonary toxicity | Increased toxicity with NSAIDs, trimethoprim-sulfamethoxazole, and other folate antagonists | Avoid when eGFR is under 50 mL/min/1.73 m² per current Canadian labelling; give with folic acid per usual practice. |
| Azathioprine | Adults: 2-3 mg/kg/day PO | Myelosuppression, hepatotoxicity, GI upset, increased malignancy risk with long-term use | Severe myelosuppression with allopurinol (reduce azathioprine dose substantially if co-administered); reduced efficacy of warfarin | Dose according to thiopurine methyltransferase (TPMT) activity where available. |
| Mycophenolate mofetil | Adults: 2-3 g/day PO in divided doses | GI upset (diarrhea common), myelosuppression, increased infection risk | Reduced absorption with antacids or cholestyramine; avoid live vaccines during treatment | Particularly reasonable when interstitial lung disease is a prominent feature, or when methotrexate/azathioprine are contraindicated or not tolerated. |
| Tacrolimus | Adults: Per trough-level-guided dosing | Nephrotoxicity, hypertension, tremor, hyperglycemia | Numerous CYP3A4 interactions; avoid with other nephrotoxic agents where possible | Dosed to a target trough level; a preferred steroid-sparing option when antisynthetase-associated or other interstitial lung disease is prominent. |
Cutaneous-Directed Therapy
The skin disease of DM is frequently more corticosteroid-resistant than the myositis and often needs its own additional therapy.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Hydroxychloroquine | Adults: 200-400 mg/day PO, dosed to actual body weight (not to exceed about 5 mg/kg/day) | Retinopathy with long-term use, GI upset, rare cardiomyopathy or QTc prolongation | Additive QTc prolongation with other QTc-prolonging drugs | Arrange baseline and annual ophthalmologic screening for retinopathy after 5 years of use, sooner with risk factors. |
| Clobetasol propionate (topical) | Application: Apply once or twice daily to affected areas | Skin atrophy, striae, telangiectasia with prolonged use | None significant with topical use at recommended doses | Reserve for localized, particularly stubborn cutaneous areas alongside systemic therapy and photoprotection. |
Refractory or Severe Disease
Reserved for disease not controlled by an adequate trial of first-choice steroid-sparing agents, or for genuinely emergent presentations.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Immunoglobulin (human), IV (IVIG) | Adults: 2 g/kg IV, divided over 2-5 days, approximately every 4 weeks | Headache, aseptic meningitis, renal dysfunction, thromboembolism, hemolysis | May blunt live-vaccine response for a period afterward | The best randomized-trial evidence specifically in DM; premedicate for infusion reactions and ensure adequate hydration. |
| Rituximab | Dosing: Per specialist-directed protocol | Infusion reactions, infection risk, hypogammaglobulinemia, rare progressive multifocal leukoencephalopathy | Avoid live vaccines during and after treatment per usual practice | Particularly effective in myositis-autoantibody-positive patients and in juvenile-onset disease. |
| Cyclophosphamide | Dosing: Per specialist-directed protocol | Myelosuppression, hemorrhagic cystitis, infertility risk, infection risk, secondary malignancy with cumulative exposure | Additive myelosuppression with other cytotoxic/immunosuppressive agents | Reserved for rapidly progressive interstitial lung disease refractory to first-line combination therapy; coordinate with a tertiary interstitial lung disease centre. |
Supportive Therapy Alongside Long-Term Corticosteroids
Standard bone- and GI-protective bundle for any patient on a prolonged corticosteroid course.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Calcium carbonate + vitamin D3 | Adults: Combo: calcium carbonate 500-1000 mg elemental PO daily + vitamin D3 800-2000 IU PO daily | GI upset, constipation, hypercalcemia with excessive intake | Reduced absorption of concurrently administered levothyroxine, tetracyclines, or fluoroquinolones if not spaced apart | Combine with usual bone-density monitoring and bisphosphonate therapy where indicated. |
| Pantoprazole | Adults: 40 mg PO once daily | Headache, GI upset, rare hypomagnesemia with long-term use | May reduce absorption of drugs requiring an acidic environment (e.g., certain azole antifungals) | Reserve for patients with corticosteroid-related reflux or another clear GI-protective indication rather than routine universal use. |
References
- Dermatomyositis: Clinical features and pathogenesis — Journal of the American Academy of Dermatology (DeWane ME, Waldman R, Lu J). J Am Acad Dermatol 2020;82(2):267-281
- Characteristics of Patients With Adult-Onset Dermatomyositis at 2 Tertiary Care Centres in Ontario, Canada — Journal of Cutaneous Medicine and Surgery (Metko D, Bednar DE, Alkhayal F, Pavlova V, Legault K, Abu-Hilal M). J Cutan Med Surg 2025;29(2):124-130
- International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative — Nature Reviews Rheumatology (Oldroyd AGS, Callen JP, Chinoy H, et al.). Nat Rev Rheumatol 2023;19(12):805-817
- A systematic review and meta-analysis on the prevalence and clinical characteristics of dysphagia in patients with dermatomyositis — Neurogastroenterology & Motility (Cheng I, Wong CS). Neurogastroenterol Motil 2023;35(9):e14572
- 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups — Arthritis & Rheumatology, International Myositis Classification Criteria Project Consortium (Lundberg IE, Tjärnlund A, Bottai M, et al.). Arthritis Rheumatol 2017;69(12):2271-2282
- British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy — Rheumatology, British Society for Rheumatology Standards, Audit and Guidelines Working Group (Oldroyd AGS, Lilleker JB, Amin T, et al.). Rheumatology (Oxford) 2022;61(5):1760-1768
- Trial of Intravenous Immune Globulin in Dermatomyositis — New England Journal of Medicine, ProDERM Trial Group (Aggarwal R, Charles-Schoeman C, Schessl J, et al.). N Engl J Med 2022;387(14):1264-1278
- Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial — Arthritis & Rheumatism, RIM Study Group (Oddis CV, Reed AM, Aggarwal R, et al.). Arthritis Rheum 2013;65(2):314-324
- Consensus-based recommendations for the management of juvenile dermatomyositis — Annals of the Rheumatic Diseases, SHARE Initiative (Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, et al.). Ann Rheum Dis 2017;76(2):329-340
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.